Plain-English translation of NCT05849857 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with follicular lymphoma—a slow-growing blood cancer—whose cancer has come back or stopped responding to initial treatment within the first two years. is a special type of antibody that helps your own immune cells find and attack cancer cells. The research team wants to see whether this medication helps people live longer without their cancer getting worse compared to standard second-line treatments.
About one in four people with follicular lymphoma don't respond well to their first treatment, or their cancer comes back quickly, and they tend to do poorly with standard second treatments. This medication has shown very promising results in patients with harder-to-treat lymphomas, so researchers hope it may offer a better option for this group.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication under your skin on a set schedule: a small starting dose in week 1, then larger doses in weeks 2 and 3 of your first cycle, followed by monthly injections for up to 8 cycles (about 6 months). If your cancer responds well, you would stop treatment and be followed. If your cancer partially responds or stabilizes, you may continue treatment for up to 17 cycles total. You'll have regular clinic visits for injections, blood tests, and imaging scans to check how your body is responding.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Finland
Norway